-
2024-517666-41-00
5
2023-03-13
Prostate Cancer
-
2023-505065-91-00
4
2023-01-30
Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
-
2024-514826-22-00
7
2022-12-05
Part A: Patients with advanced solid tumors or lymphomas.
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-514139-50-00
5
2022-11-14
Multiple myeloma
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-504984-17-00
7
2022-10-05
Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, o
-
2023-508852-21-00
4
2022-06-10
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
-
2024-516331-27-00
3
2022-06-10
Participants with BRAF and/or NRAS mutation positive tumors
-
2023-503651-10-00
7
2022-05-17
Male and female participants ≥ 18 years of age with advanced or
metast
-
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
-
2023-507119-36-00
5
2022-05-09
Malignant melanoma of the skin in patients with locally advanced and f
-
2023-509743-27-00
4
2022-04-29
Systemic sclerosis associated with interstitial lung disease
-
2024-512726-28-00
6
2022-02-14
peritoneal metastases of colorectal cancer
-
2024-513857-55-00
4
2022-02-08
Achondroplasia
-
2023-504166-37-00
4
2022-02-01
Advanced ovarian, tubal or peritoneal cancer.
-
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
-
2024-516893-31-01
5
2022-01-31
Allergic rhinoconjunctivitis due to exposure of house dust mites
-
2023-509290-22-00
6
2022-01-21
Severe Symptomatic Aortic Stenosis
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2023-507372-42-00
4
2021-09-20
Schizophrenia
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma